Published on in Vol 9, No 11 (2020): November

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/17735, first published .
Injectable Amoxicillin Versus Injectable Ampicillin Plus Gentamicin in the Treatment of Severe Pneumonia in Children Aged 2 to 59 Months: Protocol for an Open-Label Randomized Controlled Trial

Injectable Amoxicillin Versus Injectable Ampicillin Plus Gentamicin in the Treatment of Severe Pneumonia in Children Aged 2 to 59 Months: Protocol for an Open-Label Randomized Controlled Trial

Injectable Amoxicillin Versus Injectable Ampicillin Plus Gentamicin in the Treatment of Severe Pneumonia in Children Aged 2 to 59 Months: Protocol for an Open-Label Randomized Controlled Trial

Journals

  1. Shahrin L, Chisti M, Sarmin M, Rahman A, Shahid A, Islam M, Afroze F, Huq S, Ahmed T. Intravenous Amoxicillin Plus Intravenous Gentamicin for Children with Severe Pneumonia in Bangladesh: An Open-Label, Randomized, Non-Inferiority Controlled Trial. Life 2021;11(12):1299 View
  2. Korang S, Nava C, Mohana S, Nygaard U, Jakobsen J. Antibiotics for hospital-acquired pneumonia in neonates and children. Cochrane Database of Systematic Reviews 2021;2021(11) View
  3. Mamun G, Zou M, Sarmin M, Brintz B, Rahman A, Parvin I, Ackhter M, Chisti M, Leung D, Shahrin L, Kulandaipalayam Natarajan S. Derivation and validation of a clinical prediction model for risk-stratification of children hospitalized with severe pneumonia in Bangladesh. PLOS Global Public Health 2023;3(8):e0002216 View
  4. Mamun G, Sarmin M, Alam A, Afroze F, Shahrin L, Shahid A, Shaima S, Sultana N, Chisti M, Ahmed T, Srisawat N. Prevalence and predictors of magnesium imbalance among critically ill diarrheal children and their outcome in a developing country. PLOS ONE 2023;18(12):e0295824 View